Request Demo
Last update 23 Jan 2025
Jiangsu Maiweikang New Drug R & D Co Ltd
Private Company|
2018|
Jiangsu Sheng, China
Last update 23 Jan 2025
Overview
Tags
Neoplasms
Digestive System Disorders
Skin and Musculoskeletal Diseases
Antibody drug conjugate (ADC)
Monoclonal antibody
Antibody
Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Related
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
WO2022171134
Patent MiningTarget |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
CTR20243246
9MW2821对比研究者选择的化疗治疗含铂化疗失败的复发或转移性宫颈癌的随机、开放、对照、多中心Ⅲ期临床研究
[Translation] A randomized, open-label, controlled, multicenter phase III clinical study of MW2821 versus investigator-selected chemotherapy for the treatment of recurrent or metastatic cervical cancer after failure of platinum-based chemotherapy
CTR20242828
一项评估9MW2821联合特瑞普利单抗对比标准化疗一线治疗局部晚期或转移性尿路上皮癌患者的随机、对照、开放、多中心Ⅲ期临床研究
[Translation] A randomized, controlled, open-label, multicenter phase III clinical study evaluating 9MW2821 combined with toripalimab versus standard chemotherapy as first-line treatment for patients with locally advanced or metastatic urothelial carcinoma
CTR20242376
一项评估9MW2821单药或联合PD-1单抗在局部晚期或转移性三阴性乳腺癌患者中有效性和安全性的开放、多中心、II期临床研究
[Translation] An open, multicenter, phase II clinical study to evaluate the efficacy and safety of 9MW2821 alone or in combination with PD-1 monoclonal antibody in patients with locally advanced or metastatic triple-negative breast cancer
100 Clinical Results associated with Jiangsu Maiweikang New Drug R & D Co Ltd
Login to view more data
Login to view more data
100 Deals associated with Jiangsu Maiweikang New Drug R & D Co Ltd
Login to view more data
100 Translational Medicine associated with Jiangsu Maiweikang New Drug R & D Co Ltd
Login to view more data
Corporation Tree
Boost your research with our corporation tree data.
login
or
Pipeline
Pipeline Snapshot as of 24 Jan 2025
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
2
1
Phase 3 Clinical
Login to view more data
Current Projects
Login to view more data
Deal
Boost your decision using our deal data.
login
or
Translational Medicine
Boost your research with our translational medicine data.
login
or
Profit
Explore the financial positions of over 360K organizations with Synapse.
login
or
Grant & Funding(NIH)
Access more than 2 million grant and funding information to elevate your research journey.
login
or
Investment
Gain insights on the latest company investments from start-ups to established corporations.
login
or
Financing
Unearth financing trends to validate and advance investment opportunities.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free